Transplantation Using Umbilical Cord And Placental Blood
OBJECTIVES:
- Determine the response rate of patients with chronic myeloid leukemia, acute leukemia,
lymphoma, myeloma, myelodysplasia, aplastic anemia, Fanconi's anemia, histiocytosis,
hereditary immunodeficiency, or storage disorder treated with allogeneic umbilical cord
and placental blood transplantation.
- Determine the toxicity of this regimen in these patients.
- Determine survival in these patients treated with this regimen.
- Determine the incidence of graft-versus-host disease in these patients treated with
this regimen.
OUTLINE: Patients receive a standard preparative regimen for their disease. Following the
preparative regimen patients undergo umbilical cord blood stem cell transplantation on day
0.
Patients are followed every 1-2 weeks for 6 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 4-5 years.
Interventional
Primary Purpose: Treatment
Response rate
No
David G. Savage, MD
Study Chair
Herbert Irving Comprehensive Cancer Center
United States: Federal Government
CDR0000068384
NCT00008164
January 1997
Name | Location |
---|---|
Herbert Irving Comprehensive Cancer Center at Columbia University | New York, New York 10032 |